From GlobeNewswire: 2025-02-25 08:30:00

Silexion Therapeutics Corp. completed an initial study evaluating SIL-204 in orthotopic pancreatic cancer models. This study focused on SIL-204’s ability to reduce primary tumor growth and metastatic spread in clinically relevant pancreatic cancer models. The orthotopic models used in the study aim to accurately reflect human pancreatic cancer biology. Initial results from the study are expected to be shared in March 2025 and will inform Silexion’s development strategy for SIL-204. Silexion is a biotechnology company developing RNA interference therapies for KRAS-driven cancers, with a focus on improving outcomes for patients with difficult-to-treat cancers.



Read more at GlobeNewswire: Silexion Therapeutics Announces Completion of Initial Study